# Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

> **NCT06094426** · EARLY_PHASE1 · TERMINATED · sponsor: **Grit Biotechnology** · enrollment: 2 (actual)

## Conditions studied

- Solid Tumor
- Adult
- GT316

## Interventions

- **BIOLOGICAL:** GT316

## Key facts

- **NCT ID:** NCT06094426
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-26
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was terminated from a business perspective.
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06094426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06094426, "Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06094426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*